Zynteglo Archives -

The EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based

EMA finds possible link between mRNA COVID jabs and myocarditis

https://pharmaphorum.com/news/ema-backs-link-between-mrna-covid-jabs-and-myocarditis/

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of

Zynteglo halt re-ignites viral vector safety concerns; analysts

https://pharmaphorum.com/news/zynteglo-halt-re-ignites-viral-vector-safety-concerns-analysts/

It’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its

bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapy

https://pharmaphorum.com/news/bluebird-bio-baffled-after-nice-rejects/

bluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with

bluebird offers instalment payments for Zynteglo gene therapy

https://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/

bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its

bluebird claims first approval for gene therapy Zynteglo in EU

https://pharmaphorum.com/news/bluebird-claims-first-approval-for-gene-therapy-zynteglo-in-eu/

A European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy

bluebird bio gets CHMP nod for gene therapy Zynteglo

https://pharmaphorum.com/news/bluebird-bio-gets-chmp-nod-for-gene-therapy-zynteglo/

Zynteglo